Literature DB >> 7609047

vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys.

J Hoch1, S M Lang, M Weeger, C Stahl-Hennig, C Coulibaly, U Dittmer, G Hunsmann, D Fuchs, J Müller, S Sopper.   

Abstract

In previous experiments, animals infected with SIVmac239 containing a point mutation in the vpr and nef genes developed AIDS-like symptoms after early reversion of the vpr and nef genes. Here we show that two animals in which the nef gene but not the vpr gene had reverted in the first few months did not develop disease during a 3-year observation period even after reversion to a functional vpr gene 70 weeks postinfection. To study the influence of a stable vpr mutation on virus load and pathogenesis, a 43-bp deletion was introduced into the vpr gene of SIVmac239on, a nef-open mutant of SIVmac239. Four rhesus monkeys were inoculated with the vpr deletion mutant (SIV delta vpr), and two control animals were infected with SIVmac239on. Both control animals had persistent antigenemia, high cell-associated virus loads, and elevated neopterin levels. They had to be euthanized 20 and 30 weeks postinfection because of AIDS-related symptoms. However, all four rhesus monkeys inoculated with SIV delta vpr showed only transiently detectable antigenemia. The cell-associated virus loads were high in three of the four animals. Two animals with AIDS-like symptoms had to be euthanized 71 and 73 weeks postinfection. The two remaining monkeys infected with SIV delta vpr were still alive 105 weeks postinfection. In contrast to the SIVmac239on-infected animals, SIV delta vpr-infected animals had strong humoral immune responses and intermittent cellular immune responses to SIV antigens. Our data show that a functional vpr gene is not necessary for pathogenesis. However, vpr-deficient SIVmac239 variants might be slightly attenuated, allowing some animals to resist progression to disease for an extended period of time.

Entities:  

Mesh:

Year:  1995        PMID: 7609047      PMCID: PMC189293          DOI: 10.1128/JVI.69.8.4807-4813.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus.

Authors:  H Kestler; T Kodama; D Ringler; M Marthas; N Pedersen; A Lackner; D Regier; P Sehgal; M Daniel; N King
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

Review 4.  Neopterin as a marker for activated cell-mediated immunity: application in HIV infection.

Authors:  D Fuchs; A Hausen; G Reibnegger; E R Werner; M P Dierich; H Wachter
Journal:  Immunol Today       Date:  1988-05

5.  Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate.

Authors:  C Stahl-Hennig; O Herchenröder; S Nick; M Evers; M Stille-Siegener; K D Jentsch; F Kirchhoff; T Tolle; T J Gatesman; W Lüke
Journal:  AIDS       Date:  1990-07       Impact factor: 4.177

Review 6.  Pathology of simian immunodeficiency virus induced disease.

Authors:  A A Lackner
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

7.  Studies of bromouracil deoxyriboside substitution in DNA of bean roots (Vicia faba).

Authors:  W F Haut; J H Taylor
Journal:  J Mol Biol       Date:  1967-06-28       Impact factor: 5.469

8.  Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein.

Authors:  X F Yu; M Matsuda; M Essex; T H Lee
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

9.  Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1.

Authors:  D Fuchs; M Banekovich; A Hausen; J Hutterer; G Reibnegger; E R Werner; F D Gschnait; M P Dierich; H Wachter
Journal:  Clin Chem       Date:  1988-12       Impact factor: 8.327

10.  Progression to AIDS in the absence of a gene for vpr or vpx.

Authors:  J S Gibbs; A A Lackner; S M Lang; M A Simon; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  39 in total

1.  The first HxRxG motif in simian immunodeficiency virus mac239 Vpr is crucial for G(2)/M cell cycle arrest.

Authors:  Sandra M Mueller; Sabine M Lang
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.

Authors:  Navid Madani; Amy M Hubicki; Ana Luisa Perdigoto; Martin Springer; Joseph Sodroski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

5.  Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2.

Authors:  B R Gundlach; H Linhart; U Dittmer; S Sopper; S Reiprich; D Fuchs; B Fleckenstein; G Hunsmann; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.

Authors:  B Rosenwirth; P ten Haaft; W M Bogers; I G Nieuwenhuis; H Niphuis; E M Kuhn; N Bischofberger; J L Heeney; K Uberla
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes.

Authors:  B J Campbell; V M Hirsch
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

Authors:  M S Wyand; K H Manson; M Garcia-Moll; D Montefiori; R C Desrosiers
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Vpr-induced cell cycle arrest is conserved among primate lentiviruses.

Authors:  V Planelles; J B Jowett; Q X Li; Y Xie; B Hahn; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.